KEGG   DISEASE: Hepatocellular carcinoma
H00048                      Disease                                

Hepatocellular carcinoma;
Liver cancer
Hepatocellular carcinoma (HCC) is a major type of primary liver cancer and one of the rare human neoplasms etiologically linked to viral factors. It has been shown that, after HBV/HCV infection and alcohol or aflatoxin B1 exposure, genetic and epigenetic changes occur. The recurrent mutated genes were found to be highly enriched in multiple key driver signaling processes, including telomere maintenance, TP53, cell cycle regulation, the Wnt/beta-catenin pathway (CTNNB1 and AXIN1), the phosphatidylinositol-3 kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway. Recent studies using whole-exome sequencing have revealed recurrent mutations in new driver genes involved in the chromatin remodelling (ARID1A and ARID2) and the oxidative stress (NFE2L2) pathways.
Human diseases [BR:br08402]
  Cancers of the digestive system
   H00048  Hepatocellular carcinoma
Human diseases in ICD-11 classification [BR:br08403]
 02 Neoplasms
  Malignant neoplasms, except primary neoplasms of lymphoid, haematopoietic, central nervous system or related tissues
   Malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, haematopoietic, central nervous system or related tissues
    Malignant neoplasms of digestive organs
     2C12  Malignant neoplasms of liver or intrahepatic bile ducts
      H00048  Hepatocellular carcinoma
Tumor markers [br08442.html]
Cancer-associated carbohydrates [br08441.html]
hsa05225  Hepatocellular carcinoma
hsa05161  Hepatitis B
hsa05160  Hepatitis C
hsa05200  Pathways in cancer
hsa05206  MicroRNAs in cancer
nt06110  MAPK signaling (viruses and bacteria)
nt06114  PI3K signaling (viruses)
nt06118  TGFB signaling (viruses)
nt06119  JAK-STAT signaling (viruses)
nt06121  TLR signaling (viruses and bacteria)
nt06122  IFN signaling (viruses)
nt06123  TNF signaling (viruses and bacteria)
nt06124  Chemokine signaling (viruses)
nt06130  Cell cycle (viruses)
nt06131  Apoptosis (viruses and bacteria)
nt06133  RLR signaling (viruses)
nt06137  OAS/RNase L pathway (viruses)
nt06140  Transcription (viruses)
nt06162  Hepatitis B virus (HBV)
nt06163  Hepatitis C virus (HCV)
nt06263  Hepatocellular carcinoma
N00005  Mutation-activated MET to RAS-ERK signaling pathway
N00044  Mutation-activated MET to PI3K signaling pathway
N00049  Mutation-activated PI3K to PI3K signaling pathway
N00052  Mutation-inactivated PTEN to PI3K signaling pathway
N00058  Mutation-activated CTNNB1 to Wnt signaling pathway
N00059  FZD7-overexpression to Wnt signaling pathway
N00071  Deleted p16(INK4a) to p16-cell cycle G1/S
N00074  Loss of RB1 to cell cycle G1/S
N00115  Mutation-inactivated TP53 to transcription
N00228  TGFA-overexpression to PLCG-PKC signaling pathway
N00230  TGFA-overexpression to RAS-ERK signaling pathway
N00232  TGFA-overexpression to PI3K signaling pathway
N00235  IGF2-overexpression to RAS-ERK signaling pathway
N00236  IGF2-overexpression to PI3K signaling pathway
N00237  IGF1R-overexpression to RAS-ERK signaling pathway
N00238  IGF1R-overexpression to PI3K signaling pathway
N00240  TERT-overexpression to telomerase activity
N00241  TGFBR2-reduced expression to TGF-beta signaling pathway
N00242  Mutation-inactivated AXIN to Wnt signaling pathway
N00244  Mutation-inactivated KEAP1 to KEAP1-NRF2 signaling pathway
N00245  Mutation-activated NRF2 to KEAP1-NRF2 signaling pathway
N00246  HGF-overexpression to RAS-ERK signaling pathway
N00247  HGF-overexpression to PI3K signaling pathway
N00248  MET-overexpression to RAS-ERK signaling pathway
N00249  MET-overexpression to PI3K signaling pathway
N00267  HBV HBx to PI3K signaling pathway
N00268  HBV HBx to RIG-I-like receptor signaling pathway
N00269  HCV core to TNF-NFKB signaling pathway
N00270  HCV Core to IFN signaling pathway
N00271  HCV NS3/4A to RIG-I-like receptor signaling pathway
N00272  HCV NS5A to PI3K signaling pathway
N00273  HCV NS5A to oligoadenylate synthetase (OAS)/RNase L pathway
N00274  HCV NS5A to RAS-ERK signaling pathway
N00516  HCV NS3/4A to TLR3-IRF3 signaling pathway
N00517  HCV NS3/4A to TLR3-IRF3 signaling pathway
N00518  HCV Core to ERK signaling pathway
N00519  HCV Core to ERK signaling pathway
N00520  HCV NS5A to p21-cell cycle G1/S
N00521  HCV Core to p21-cell cycle G1/S
N00522  HCV NS3 to p21-cell cycle G1/S
N00523  HCV Core to p21-cell cycle G1/S
N00524  HCV NS5A to extrinsic apoptotic pathway
N00525  HCV NS5A to TNF-NFKB signaling pathway
N00526  HCV NS3 to crosstalk between extrinsic and intrinsic apoptotic pathways
N00527  HCV Core to crosstalk between extrinsic and intrinsic apoptotic pathways
N00528  HCV core to extrinsic apoptotic pathway
N00529  HCV core to RXRA/PPARA-mediated transcription
N00530  HCV core to RXRA/LXRA-mediated transcription
N00531  HBV HBx to TGF-beta signaling pathway
N00532  HBV HBx to Egr-mediated transcription
N00533  HBV HBx to Crosstalk between extrinsic and intrinsic apoptotic pathways
N00534  HBV HBx to Crosstalk between extrinsic and intrinsic apoptotic pathways
N00535  HBV HBx to p53-mediated transcription
N00537  HBV HBx to cell cycle G1/S
N00539  HBV HBx to Ca2+-PYK2-RAS-ERK signaling pathway
N00540  HBV HBx to RAS-ERK signaling pathway
N00541  HBV HBx to RAS-ERK signaling pathway
N00543  HBV HBx to JNK signaling pathway
N00544  HBV HBx to CREB-mediated transcription
N00545  HBV HBx to ERK signaling pathway
N00547  HBV LHBs to PKC-ERK signaling pathway
N00548  HBV HBx to Jak-STAT signaling pathway
N00549  HBV HBeAg to TLR2/4-NFKB signaling pathway
N00550  HBV HBeAg to TLR2/4-NFKB signaling pathway
N00551  HBV HBs to TLR2/4-MAPK signaling pathway
N00552  HBV pol to TLR3-IRF3 signaling pathway
N00554  HBV HBe to TLR4-IRF3/7 signaling pathway
N00555  HBV HBe to TLR4-IRF3/7 signaling pathway
N00556  HBV HBe to TLR2/4-NFKB signaling pathway
N00557  HBV HBe to TLR2/4-NFKB signaling pathway
N00558  HBV pol to IFN signaling pathway
N01365  TCDD to Ahr signaling pathway
N01366  BaP to Ahr signaling pathway
N01378  AFB1 to DNA adducts
N01383  NDMA to DNA adducts
N01390  p,p'-DDT to SOD/Cat-mediated ROS neutralization
N01406  Ethanol to CYP-mediated metabolism
N01407  Metals to JNK signaling pathway
N01408  Metals to RAS-ERK signaling pathway
N01409  Metals to PI3K signaling pathway
N01410  Metals to NFKB signaling pathway
N01411  Metals to NFKB signaling pathway
N01412  Metals to HTF-1 signaling pathway
N01413  Metals to KEAP1-NRF2 signalig pathway
TGFA (overexpression) [HSA:7039] [KO:K08774]
IGF2 (overexpression) [HSA:3481] [KO:K13769]
IGF1R (overexpression) [HSA:3480] [KO:K05087]
MYC (amplification) [HSA:4609] [KO:K04377]
RB1 (loss) [HSA:5925] [KO:K06618]
TERT (overexpression) [HSA:7015] [KO:K11126]
TP53 (mutation) [HSA:7157] [KO:K04451]
p16 (deletion) [HSA:1029] [KO:K06621]
PTEN (mutation) [HSA:5728] [KO:K01110]
TGFBR2 (reduced expression) [HSA:7048] [KO:K04388]
FZD7 (overexpression) [HSA:8324] [KO:K02432]
CTNNB1 (mutation) [HSA:1499] [KO:K02105]
AXIN1 (mutation) [HSA:8312] [KO:K02157]
KEAP1 (mutation) [HSA:9817] [KO:K10456]
NFE2L2 (mutation) [HSA:4780] [KO:K05638]
HGF (overexpression) [HSA:3082] [KO:K05460]
MET (mutation, overexpression) [HSA:4233] [KO:K05099]
PIK3CA (mutation) [HSA:5290] [KO:K00922]
ARID1A (mutation) [HSA:8289] [KO:K11653]
ARID2 (mutation) [HSA:196528] [KO:K11765]
Aflatoxins (naturally occurring mixtures of) [CPD:C06800]
Alcoholic beverages
Opisthorchis viverrini (infection with)
Radium-224 and its decay products [CPD:C16455]
*Chimney sweeping
*2,3,7,8-Tetrachlorodibenzo-para-dioxin [CPD:C07557]
*Thorium-232 and its decay products, administered intravenously as a colloidal dispersion of thorium232 dioxide
*Tobacco smoking and tobacco smoke
*: Although this is a risk factor for liver cancer in general, the strength of association with different histological tumor types is not well understood.
Hepatitis B virus [GN:T40004]
Hepatitis C virus [GN:T40066]
Sorafenib tosylate [DR:D06272]
Regorafenib hydrate [DR:D10137]
Cabozantinib s-malate [DR:D10095]
Lenvatinib mesylate [DR:D09920]
Bevacizumab [DR:D06409]
Ipilimumab [DR:D04603]
Nivolumab [DR:D10316]
Pembrolizumab [DR:D10574]
Ramucirumab [DR:D09371]
Atezolizumab [DR:D10773]
ICD-O: 8170/3, Tumor type: Hepatocellular carcinoma (liver cell carcinoma)
Other DBs
ICD-11: 2C12.0
ICD-10: C22
MeSH: D006528
Kudo M
Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma.
Dig Dis 29:289-302 (2011)
Niu ZS, Niu XJ, Wang WH
Genetic alterations in hepatocellular carcinoma: An update.
World J Gastroenterol 22:9069-9095 (2016)
Breuhahn K, Longerich T, Schirmacher P
Dysregulation of growth factor signaling in human hepatocellular carcinoma.
Oncogene 25:3787-800 (2006)
Whittaker S, Marais R, Zhu AX
The role of signaling pathways in the development and treatment of hepatocellular carcinoma.
Oncogene 29:4989-5005 (2010)
Minguez B, Tovar V, Chiang D, Villanueva A, Llovet JM
Pathogenesis of hepatocellular carcinoma and molecular therapies.
Curr Opin Gastroenterol 25:186-94 (2009)
Suriawinata A, Xu R
An update on the molecular genetics of hepatocellular carcinoma.
Semin Liver Dis 24:77-88 (2004)
Taguchi K, Motohashi H, Yamamoto M
Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution.
Genes Cells 16:123-40 (2011)
Yoo NJ, Kim HR, Kim YR, An CH, Lee SH
Somatic mutations of the KEAP1 gene in common solid cancers.
Histopathology 60:943-52 (2012)
Guichard C, Amaddeo G, Imbeaud S, Ladeiro Y, Pelletier L, Maad IB, Calderaro J, Bioulac-Sage P, Letexier M, Degos F, Clement B, Balabaud C, Chevet E, Laurent A, Couchy G, Letouze E, Calvo F, Zucman-Rossi J
Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma.
Nat Genet 44:694-8 (2012)
Granito A, Guidetti E, Gramantieri L
c-MET receptor tyrosine kinase as a molecular target in advanced hepatocellular carcinoma.
J Hepatocell Carcinoma 2:29-38 (2015)
Lee JW, Soung YH, Kim SY, Lee HW, Park WS, Nam SW, Kim SH, Lee JY, Yoo NJ, Lee SH
PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas.
Oncogene 24:1477-80 (2005)
Huang J, Deng Q, Wang Q, Li KY, Dai JH, Li N, Zhu ZD, Zhou B, Liu XY, Liu RF, Fei QL, Chen H, Cai B, Zhou B, Xiao HS, Qin LX, Han ZG
Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma.
Nat Genet 44:1117-21 (2012)
Nault JC, Mallet M, Pilati C, Calderaro J, Bioulac-Sage P, Laurent C, Laurent A, Cherqui D, Balabaud C, Zucman-Rossi J
High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions.
Nat Commun 4:2218 (2013)
PMID:17295177 (gene, tumor type)
Villanueva A, Newell P, Chiang DY, Friedman SL, Llovet JM.
Genomics and signaling pathways in hepatocellular carcinoma.
Semin Liver Dis 27:55-76 (2007)
PMID:11935086 (gene, tumor type)
Rocken C, Carl-McGrath S.
Pathology and pathogenesis of hepatocellular carcinoma.
Dig Dis 19:269-78 (2001)
PMID:17051452 (tumor type)
Spangenberg HC, Thimme R, Blum HE.
Serum markers of hepatocellular carcinoma.
Semin Liver Dis 26:385-90 (2006)
Thorgeirsson SS, Grisham JW.
Molecular pathogenesis of human hepatocellular carcinoma.
Nat Genet 31:339-46 (2002)
PMID:15760280 (carcinogen)
Schottenfeld D, Beebe-Dimmer JL.
Advances in cancer epidemiology: understanding causal mechanisms and the evidence for implementing interventions.
Annu Rev Public Health 26:37-60 (2005)
PMID:15757802 (carcinogen)
McGlynn KA, London WT.
Epidemiology and natural history of hepatocellular carcinoma.
Best Pract Res Clin Gastroenterol 19:3-23 (2005)
PMID:15489140 (carcinogen)
Wogan GN, Hecht SS, Felton JS, Conney AH, Loeb LA.
Environmental and chemical carcinogenesis.
Semin Cancer Biol 14:473-86 (2004)
PMID:11285186 (carcinogen)
Smela ME, Currier SS, Bailey EA, Essigmann JM.
The chemistry and biology of aflatoxin B(1): from mutational spectrometry to carcinogenesis.
Carcinogenesis 22:535-45 (2001)
PMID:15928434 (carcinogen)
Khurana S, Dubey ML, Malla N.
Association of parasitic infections and cancers.
Indian J Med Microbiol 23:74-9 (2005)
PMID:10564925 (carcinogen)
Nekolla EA, Kellerer AM, Kuse-Isingschulte M, Eder E, Spiess H.
Malignancies in patients treated with high doses of radium-224.
Radiat Res 152:S3-7 (1999)
PMID:9498904 (carcinogen)
Boffetta P, Jourenkova N, Gustavsson P.
Cancer risk from occupational and environmental exposure to polycyclic aromatic hydrocarbons.
Cancer Causes Control 8:444-72 (1997)
PMID:15660110 (carcinogen)
Luch A.
Nature and nurture - lessons from chemical carcinogenesis.
Nat Rev Cancer 5:113-25 (2005)
PMID:12556326 (carcinogen)
Harrison JD, Muirhead CR.
Quantitative comparisons of cancer induction in humans by internally deposited radionuclides and external radiation.
Int J Radiat Biol 79:1-13 (2003)

» Japanese version

DBGET integrated database retrieval system